Researchers identified a six-gene pattern predicting venetoclax response in multiple myeloma. This genetic insight allows for ...

The single-center report showed the therapy had a favorable safety profile and manageable side effects in children with ...

While B-ALL is the most common childhood cancer and one of the most treatable, some patients face grim outcomes after they ...

Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...

Researchers found no significant differences in the risk of overall adverse events (AEs), but there were significant differences in grade 3 or higher AEs, serious AEs, treatment discontinuations due ...

ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual ...

In a recent study published in Nature Cancer, researchers explore treatment resistance and relapse in T-cell acute ...

ALL, certain drugs work for some patients who relapse, but these drugs are not effective for all patients who relapse.

An expert highlighted unmet needs in treating T-cell acute lymphoblastic leukemia and where research may focus in the future.

Aptose and Hanmi Pharmaceutical Co-developing Triplet Therapy of Tuspetinib with Azacitidine and Venetoclax for Newly ...